{"entity":{"id":"inv-6452","kind":"drug","name":"INV-6452","aka":[],"tldr":"INV-6452 is an experimental form not stated by the company or the registry from Shenzhen Ionova Life Sciences, in phase 1 trials for HR-positive HER2-negative breast cancer, ovarian cancer and endometrial cancer.","summary":"INV-6452 is a form not stated by the company or the registry (oral) from Shenzhen Ionova Life Sciences. Taken orally once daily in HR-positive, HER2-negative breast cancer and other solid tumours; no source found states its target or mechanism. Its furthest stage is phase 1, for HR-positive HER2-negative breast cancer, ovarian cancer and endometrial cancer. ClinicalTrials.gov registers it in one study linked below. Phase 1/2 first-in-human, recruiting, started 2025-07-04 (registry). Whether it works in people has not been established unless a trial below reports it.","status":"phase-1","asOf":"2026-11-03","links":[{"label":"Shenzhen Ionova Life Sciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07612891"},{"label":"Shenzhen Ionova Life Sciences: clinicaltrials.gov","url":"https://clinicaltrials.gov/api/v2/studies/NCT07612891"},{"label":"ClinicalTrials.gov: trials of INV-6452","url":"https://clinicaltrials.gov/search?intr=INV-6452"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["breast-hr-positive","ovarian","endometrial"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":["shenzhen-ionova-life-sciences"],"institutions":[],"pathways":[],"terms":[],"trials":["nct07612891"],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo gap audit, class 5 (company pipeline pages and ClinicalTrials.gov v2)","editedOn":"2026-11-03"},"code":"INV-6452","modality":"Form not stated by the company or the registry (oral)","mechanism":"Taken orally once daily in HR-positive, HER2-negative breast cancer and other solid tumours; no source found states its target or mechanism.","approvals":[],"mechanismSteps":[],"toxicity":[],"access":[],"regulatoryEvents":[]},"route":"/drugs/inv-6452/","neighbours":{"cancer":[{"id":"endometrial","kind":"cancer","name":"Endometrial cancer","route":"/cancers/endometrial/"},{"id":"breast-hr-positive","kind":"cancer","name":"HR-positive / HER2-negative breast cancer","route":"/cancers/breast-hr-positive/"},{"id":"ovarian","kind":"cancer","name":"Ovarian cancer","route":"/cancers/ovarian/"}],"company":[{"id":"shenzhen-ionova-life-sciences","kind":"company","name":"Shenzhen Ionova Life Sciences","route":"/companies/shenzhen-ionova-life-sciences/"}],"trial":[{"id":"nct07612891","kind":"trial","name":"A Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of INV-6452 in Adult Patients With Hormone Receptor Positive, Human Epidermal Growth Factor Receptor 2 Negative (HR+/HER2-) Advanced/Metastatic Breast Cancer or Locally Advanced/Metastatic Solid Tumor","route":"/trials/nct07612891/"}]}}